Navigation Links
Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics

Combined Company Renamed Cornerstone Therapeutics Inc. and to Continue Trading on NASDAQ under "CRTX"

CARY, N.C., Nov. 3 /PRNewswire-FirstCall/ -- Cornerstone BioPharma Holdings, Inc., a specialty pharmaceutical company focused on developing and commercializing prescription medications for respiratory disorders, today announced the completion of its previously announced merger with Critical Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing innovative products for respiratory and inflammatory diseases. The combined company has been renamed Cornerstone Therapeutics Inc. and will continue to trade on The NASDAQ Capital Market under the ticker symbol "CRTX".

Under the terms of the merger, which is a stock-for-stock merger intended to qualify as a tax-free reorganization, all outstanding shares of Cornerstone BioPharma's common stock were converted into and exchanged for the right to receive shares of Critical Therapeutics' common stock, and all outstanding Cornerstone BioPharma options and warrants were assumed by Critical Therapeutics and became options and warrants to acquire Critical Therapeutics' common stock.

Immediately prior to the consummation of the merger, Critical Therapeutics effected a 10-to-1 reverse stock split of its common stock. As a result of the reverse stock split and the merger, Cornerstone BioPharma's and Critical Therapeutics' stockholders now own approximately 70 and 30 percent of the combined company's common stock, respectively, after giving effect to shares issuable under outstanding Cornerstone BioPharma options and warrants, but excluding shares issuable under outstanding Critical Therapeutics options and warrants.

Craig A. Collard, president and chief executive officer of Cornerstone BioPharma, will be president and chief executive officer of the combined company. Brian Dickson, M.D., chief medical officer of Cornerstone BioPharma, will be the chief medical officer of the combined company. Steven Lutz, executive vice president, commercial operations of Cornerstone BioPharma, will be executive vice president, manufacturing and trade of the combined company. George Esgro, vice president, sales and marketing of Cornerstone BioPharma, will be vice president, sales of the combined company. David Price, executive vice president, finance and chief financial officer of Cornerstone BioPharma, will be executive vice president, finance and chief financial officer of the combined company. Scott Townsend, senior vice president of legal affairs and general counsel of Critical Therapeutics, will be executive vice president of legal affairs and general counsel of the combined company.

"We are pleased to complete our merger with Critical Therapeutics and begin executing on our business plan," said Mr. Collard. "Both companies come off strong third quarter results, and we believe the growth prospects for the combined company are significant."

Lazard acted as exclusive financial advisor and Wilmer Cutler Pickering Hale and Dorr LLP acted as legal counsel to Critical Therapeutics. Jefferies & Company, Inc. acted as exclusive financial advisor and Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. acted as legal counsel to Cornerstone BioPharma.

About Cornerstone Therapeutics

Cornerstone Therapeutics (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing prescription products for the respiratory market. The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians and key retail pharmacies with its specialty sales force. Cornerstone Therapeutics also has a deep late-stage clinical pipeline with six regulatory approval submissions expected between 2009 and 2010. The Company's commercial strategy is to grow market share for its currently marketed products using its sales and marketing capabilities, acquire non-promoted or underperforming branded pharmaceutical products and implement life cycle management techniques to maximize the value of its currently marketed products, newly acquired products and product candidates that are in development.

Safe Harbor Statement

Statements in this press release regarding benefits and synergies of the merger; the progress and timing of product development programs and related trials of the combined company; future opportunities for the combined company; the strategy, future operations, financial position, future revenues and projected costs of the combined company; prospects, plans and objectives of the combined company's management; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words 'believes,' 'plans,' 'could,' 'anticipates,' 'expects,' 'estimates,' 'plans,' 'should,' 'target,' 'will,' 'would' and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including: our ability to successfully integrate the operations and employees of Critical Therapeutics and Cornerstone BioPharma; our ability to realize anticipated synergies and cost savings from the merger; our ability to develop and maintain the necessary sales, marketing, distribution and manufacturing capabilities to commercialize our products; our ability to transition our management teams effectively; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a small number of currently marketed products; our ability to maintain regulatory approvals to market and sell our products; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Critical Therapeutics' Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, as amended, filed with the SEC and other SEC filings, including, but not limited to, those set forth in the section entitled "Risks Related to Cornerstone" beginning on page 59 of the proxy statement/prospectus Critical Therapeutics filed with the SEC pursuant to Rule 424(b)(3) on October 6, 2008, and in other filings that Cornerstone Therapeutics makes with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.

In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this release.

SOURCE Cornerstone BioPharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
2. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
3. PDL BioPharma to Actively Seek Sale of Entire Company or Its Key Assets
4. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
5. Nabi Biopharmaceuticals Announces Third Quarter 2007 Financial Results and Positive Vote from November 8, 2007 Special Stockholders Meeting
6. Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
8. Aladdin eToken First Strong Authentication Device to Achieve Certification from the SAFE-BioPharma Association
9. XTL Biopharmaceuticals Announces Financial Results for the Year Ended December 31, 2007
10. ARCA Discovery Changes Name to ARCA biopharma to Reflect Focus on Drug Commercialization
11. CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development
Post Your Comments:
(Date:11/30/2015)... DC (PRWEB) , ... November ... ... Inc. (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider Partnerships: ... lessons learned from three innovative value-based care arrangements: Essentia Health and UCare, ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair in the ... Matrix is a long-term resorbable surgical mesh intended to support and reinforce soft ...
(Date:11/30/2015)... Puerto Rico (PRWEB) , ... November 30, 2015 , ... ... active part of the San Juan Beauty Show held on November 8th and 9th ... was attended by media personalities, hair artists, renowned beauticians and top of the line ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... are pleased to announce their strategic partnership at the Radiological Society of ... Service, Inc., and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation ...
(Date:11/30/2015)... ... 30, 2015 , ... World Patent Marketing , a ... household invention that provides an economical and easy way of gaining customized curtains. ... at 2.6%," says Scott Cooper, CEO and Creative Director of World Patent Marketing. ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015   VolitionRx Limited (NYSE MKT: ... tests for a broad range of cancer types and other ... Micro Conference, which will be held December 1 - 3 in ... VolitionRx will be David Kratochvil , Chief Financial Officer ... Investor Relations. ® blood-based tests for colorectal ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
(Date:11/30/2015)... and REHOVOT, Israel , ... specialty pharmaceutical company focused on acquiring and developing innovative ... announced the appointment of Keith A. Katkin ... Gregory J. Flesher , chief executive officer for ... building successful organizations.  As chairman, he will be able ...
Breaking Medicine Technology: